medigraphic.com
ISSN 0210-5187 (Electronic)

2018, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2018; 46 (3)

Hydroa vacciniforme–like cutaneous T-cell lymphoma. Case report

Gallegos RX, Orozco N

Language: Spanish
References: 28
Page: 201-208
PDF size: 463.06 Kb.


ABSTRACT

Hydroa vacciniforme–like cutaneous T-cell lymphoma (HVLCTCL) is a clinical entity characterized by malignant proliferation of T lymphocytes with or without angiocentric invasion of blood vessels; it has an unusual presentation. Its frequency is greater in pediatric population of Mexico, Central and South America, and parts of Asia. It appears mainly in areas exposed to light, such as face, back of hands, arms and legs, with exudative and crusted papular vesicles on an erythematous base that leave varioliform scars similar to hydroa vacciniforme. In addition, facial edema can occur, as well as infiltrative nodules and suppurative ulcerative lesions. Infections with Epstein-Barr virus (EBV) have been commonly associated with T or NK cell monoclonal lymphoma with a high malignancy rate, resistance to chemotherapeutic agents and high mortality. We describe the case of a seven-year-old patient who suffered from HVLCTCL; his diagnosis was very difficult because of the complexity of the histopathological study. The patient reported belongs to a rural area in Quito, Ecuador.


REFERENCES

  1. Ramos RC, Cortez F, Quijano E, Carayhua D, Jiménez H, Rivera A. Linfoma tipo hidroa: presentación de un caso. Rev Soc Peruana de Dermatología. 2011; 21 (3): 126-129.

  2. Quintanilla-Martinez L, Ridaura C, Nagl F, Sáez-de-Ocariz M, Durán-McKinster C, Ruiz-Maldonado R et al. Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood. 2013; 122 (18): 3101-3110.

  3. Sawada A, Inoue M, Koyama-Sato M, Kondo O, Yamada K, Shimizu M et al. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases. Biol Blood Marrow Transplant. 2014; 20 (2): 214-221.

  4. Ruiz-Maldonado R, Parrilla FM, Orozco-Covarrubias ML, Ridaura C, Tamayo-Sánchez L, Duran-McKinster C. Edematous, scarring vasculitic panniculitis: a new multisystemic disease with malignant potential. J Am Acad Dermatol. 1995; 32 (1): 37-44.

  5. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014; 70 (2): 205.e1-16; quiz 221-222.

  6. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001; 98 (2): 280-286.

  7. Durán-McKinster C, Ruiz-Maldonado R. Hidroa vacciniforme-like o enfermedad de Ruiz Maldonado. Dermatología Rev Mex. 2013; 57 (6): 464-467.

  8. Kanazawa T, Hiramatsu Y, Iwata S, Siddiquey M, Sato Y, Suzuki M et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014; 20 (19): 5075-5084.

  9. Florencia-Fernández M, Bettina-Cervini A, Chantada G, Pierini AM. Linfoma cutáneo de células T hidroa vacciniforme-like. Arch Argent Dermatol. 2013; 63 (6): 219-225.

  10. Lim MS, de Leval L, Quintanilla-Martinez L. Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms. J Hematop. 2009; 2 (2): 65-73.

  11. Beltrán BE, Maza I, Moisés-Alfaro CB, Vasquez L, Quiñones P, Morales D et al. Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol. 2014; 89 (12): 1160-1161.

  12. Maldonado-García CA, Beirana-Palencia A. Hidroa vacciniforme, revisión del tema. Rev Cent Dermatol Pascua. 2006; 15 (3): 198-202.

  13. Wang RC, Chang ST, Hsieh YC, Huang WT, Hsu JD, Tseng CE et al. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan. Int J Clin Exp Pathol. 2014; 7 (5): 2430-2437.

  14. Kempf W, Kazakov DV, Kerl K. Cutaneous lymphomas: an update. Part 1: T-cell and natural killer/t-cell lymphomas and related conditions. Am J Dermatopathol. 2014; 36 (2): 105-123.

  15. Di Martino-Ortiz B, Barboza G, Moreno T, Valiente C, Buongermini A, Boggino H. Linfoma cutáneo tipo hidroa vacciniforme. Desorden linfoproliferativo asociado a infección por virus del Epstein-Barr en la infancia. Piel. 2015; 30 (7): 420-423.

  16. Sorigue M, Sancho JM. The 2016 revision of the WHO classification of lymphoid neoplasms: The clinician’s view. Med Clin (Barc). 2018; 150 (2): 64-66.

  17. Kempf W, Mitteldorf C. Pathologic diagnosis of cutaneous lymphomas. Dermatol Clin. 2015; 33 (4): 655-681.

  18. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008; 371 (9616): 945-957.

  19. Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology. 2003; 207 (1): 116-118.

  20. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005; 115 (4): 798-812.

  21. Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci. 2012; 68 (1): 45-51.

  22. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM et al. International Classification of Diseases for Oncology. 3rd edition. Malta: WHO; 2013. Disponible en: http://apps.who.int/iris/bitstream/10665/96612/1/9789241548496_eng.pdf?ua=1

  23. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002; 10 (1): 7-14.

  24. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127 (20): 2375-2390.

  25. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98 (1): 76-85.

  26. Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010; 137 (6): 1391-1397.

  27. Hahn RC, Rodrigues AM, Fontes CJ, Nery AF, Tadano T, Queiroz Lde P Jr et al. Fatal fungemia due to Paracoccidioides lutzii. Am J Trop Med Hyg. 2014; 91 (2): 394-398.

  28. Sule RR, Deshpande SG, Dharmadhikari NJ, Joshi VR. Late cutaneous syphilis. Cutis. 1997; 59 (3): 135-137.




2020     |     www.medigraphic.com